Proton radiotherapy for prostate cancer has reduced toxicity, higher cost vs other radiotherapy options

Proton radiotherapy offers some reduced toxicity over intensity-modulated radiotherapy (IMRT) in patients under the age of 65 with prostate cancer, but its cost is nearly twice that of IMRT, according to a new analysis. Stereotactic body radiotherapy (SBRT) had a slightly lower cost than IMRT, with a similar toxicity profile.
Cancer Network

One Response to “Proton radiotherapy for prostate cancer has reduced toxicity, higher cost vs other radiotherapy options”

  1. Stuart Green

    This article greatly uses the term “cost” of treatment when in reality what is being discussed is the “charge” for treatment. The charges for IMRT and SABR in the US and in the private setting in the UK are high – and these are the figures quoted in the article. The “cost” of delivering IMRT and SABR is very much lower as evidenced by the tariff prices in the UK NHS which operates on a model much more closely related to true cost.
    While there are as yet no NHS tariffs for proton radiotherapy, the cost of equipment dictates that with currently available technology the multiplier between the “cost” of proton radiotherapy and the “cost” of complex x-ray-radiotherapy is much more than the factor of 2 quoted here. Perhaps closer to a factor of 5. Presumably this changes the conclusions of the article quite considerably.